"EC approves AstraZeneca’s Calquence combo to treat MCL" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this sit ...

Shares of AstraZeneca (AZN) rose 1% on Tuesday morning after it announced that its Calquence (acalabrutinib) in combination with bendamustine and rituximab has been approved in the European Union for ...

Calquence (acalabrutinib) has potential interactions with other medications and some supplements. For example, Calquence can interact with ketoconazole and carbamazepine. Calquence is a ...

Latest preliminary data show continued promising clinical activity in NHL patients, with two complete responses (CR), three ...

AstraZeneca has received another boost to its aspirations in oncology with the FDA approval of Calquence, a next generation treatment for mantle cell lymphoma (MCL). Calquence (acalabrutinib ...

(RTTNews) - British drug major AstraZeneca Plc. (AZN.L, AZN) announced Tuesday that the European Union or EU has approved Calquence (acalabrutinib) in combination with bendamustine and rituximab ...

AstraZeneca’s Calquence (acalabrutinib) in combination with bendamustine and rituximab has been approved in the European Union (EU) for the treatment of adult patients with previously untreated mantle ...

AstraZeneca announced on Tuesday that it has secured European Commission approval for ‘Calquence’, or acalabrutinib, in combination with bendamustine and rituximab for the treatment of adult patients ...

Calquence can also be given as an outpatient while Gazyvaro-based therapy requires intravenous administration in hospital, making at a good option for older and frail patients, according to AZ.

AstraZeneca (AZ) has announced that its Calquence (acalabrutinib) regimens have been recommended by the European Medicines Agency’s human medicines committee to treat chronic lymphocytic leukaemia ...

The European Commission (EC) has approved AstraZeneca's Bruton's tyrosine kinase (BTK) inhibitor Calquence (acalabrutinib), plus bendamustine and rituximab, to treat adults with previously ...